New Data Shows Ongoing Benefits of Percutaneous MitraClip(R) Device for Patients With Mitral Reg... (enrollment by the end of2008. This s...)

New Data Shows Ongoing Benefits of Percutaneous MitraClip(R) Device for Patients With Mitral Regurgitation

Date:10/24/2007

enrollment by the end of 2008.

"This study is gathering valuable information that cardiac surgeons and interventional cardiologists have never had before. The data provides new insights about treatment considerations for patients with significant degenerative or functional mitral regurgitation," said Dr. Feldman. "We encourage physicians to refer such patients to EVEREST investigators."

Enrollment in the study is open to a range of patients:

-- Patients with either degenerative or functional MR.

-- Patients who are good surgical candidates and are open to the option of

a less invasive approach.

-- High risk patients who are not good candidates for surgery will be

enrolled in the EVEREST High Risk Registry until enrollment is complete

in this arm by the end of 2007.

More information about the EVEREST II trial is available at http://www.mitralregurgitation.org.

"Evalve remains focused on completing the EVEREST II trial and making progress toward commercialization of the MitraClip device," said Ferolyn Powell, president and chief executive officer of Evalve(R). "The data underscore that the MitraClip device has the potential to be a valuable alternative to treat patients with mitral regurgitation, providing a less invasive treatment option and enabling patients to avoid the trauma, long recovery times and complications associated with open heart surgery."

About EVEREST II

The EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) clinical research study is evaluating the safety and efficacy of the MitraClip device compared to surgical mitral valve repair or replacement. This prospective, randomized, multi-center study will enroll 279 patients at up to 42 sites in the United States and Canada. Patients are randomized 2:1 to receive the MitraClip device. The same sites are also enrolling patients in a High Risk Registry. Pat
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging

Post Your Comments:

New Data Shows Ongoing Benefits of Percutaneous MitraClip(R) Device for Patients With Mitral Reg...(enrollment by the end of2008. This s...),Health